How can lung cancer prevention and treatment strategies be improved in resource-restricted settings?
The key to overcoming barriers to effective prevention and treatment in resource-restricted settings involves cooperation between multiple organisations, including medical societies, patient groups, pharmaceutical companies and regulatory agencies
Improving patient involvement in rare cancers
Facilitating an open dialogue with patients, to better understand their needs, makes research efforts more valuable in the long-term
Patients as partners to address unmet needs in sarcoma
However, there are still many obstacles faced by investigators in achieving effective patient involvement in research
Improving collaboration to expedite early-phase research in oncology
Among all the stakeholders involved, oncology societies can play a pivotal role to facilitate efficient clinical investigations
What are the consequences of ‘pandemomics’ in gynaecological cancers?
As science and innovations continue to progress in gynaecological oncology, there is a need to rethink our perceptions to ensure clinical management and research advance accordingly
Is there still a future for cancer vaccines?
Despite generally disappointing clinical trial results, technological innovations mean that realising the potential for cancer vaccines could be just around the corner
Is combining radiotherapy and immunotherapy a viable treatment option?
Conflicting clinical results on the benefits of combined radiotherapy and immunotherapy may derive from differences in treatment sequencing
Rare cancers in Asia – the value of registry data in low-resourced settings
While some challenges associated with rare cancers are similar in Europe and Asia, resources and differing epidemiology need to be considered when coming up with solutions
Equity among oncologists is far from being achieved in the Chinese culture
Results from a pilot study show that work–family balance is the biggest challenge to career progression for young women
New targets for off-the-shelf treatments open up the field of precision immunotherapy
The identification of mutation-derived neoantigens may help elicit antitumour immune responses in patients with cancer, but this approach is challenging